Research Analysts Offer Predictions for SLDB FY2030 Earnings

by · The Markets Daily

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Equities researchers at HC Wainwright raised their FY2030 earnings estimates for Solid Biosciences in a report released on Wednesday, June 3rd. HC Wainwright analyst A. He now expects that the company will post earnings per share of $1.88 for the year, up from their previous forecast of $1.81. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($1.81) per share.

SLDB has been the subject of a number of other research reports. Guggenheim began coverage on shares of Solid Biosciences in a research report on Friday, March 20th. They set a “buy” rating and a $26.00 price target for the company. Chardan Capital reissued a “buy” rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of Solid Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Truist Financial raised shares of Solid Biosciences to a “strong-buy” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.82.

View Our Latest Research Report on Solid Biosciences

Solid Biosciences Trading Up 4.1%

SLDB stock opened at $6.85 on Thursday. Solid Biosciences has a twelve month low of $3.41 and a twelve month high of $8.87. The company has a market capitalization of $674.38 million, a P/E ratio of -3.51 and a beta of 2.43. The firm has a 50 day simple moving average of $7.41 and a 200-day simple moving average of $6.49.

Solid Biosciences (NASDAQ:SLDB – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12).

Hedge Funds Weigh In On Solid Biosciences

A number of institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC grew its stake in Solid Biosciences by 0.6% during the 1st quarter. Perceptive Advisors LLC now owns 11,906,646 shares of the company’s stock valued at $85,728,000 after acquiring an additional 73,107 shares in the last quarter. Bank of America Corp DE grew its stake in Solid Biosciences by 12.3% during the 1st quarter. Bank of America Corp DE now owns 386,793 shares of the company’s stock valued at $2,785,000 after acquiring an additional 42,499 shares in the last quarter. Stempoint Capital LP acquired a new stake in shares of Solid Biosciences during the 1st quarter valued at about $1,407,000. Janus Henderson Group PLC acquired a new stake in shares of Solid Biosciences during the 1st quarter valued at about $28,877,000. Finally, Ally Bridge Group NY LLC lifted its holdings in shares of Solid Biosciences by 85.4% during the 1st quarter. Ally Bridge Group NY LLC now owns 766,974 shares of the company’s stock valued at $5,522,000 after buying an additional 353,349 shares during the last quarter. Hedge funds and other institutional investors own 81.46% of the company’s stock.

About Solid Biosciences

(Get Free Report)

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.

See Also